Industry’s CER Efforts Should Follow PCORI Methods, Cmte. Member Yancy Says
This article was originally published in The Pink Sheet Daily
Pharma companies’ comparative effectiveness research should be “in sync” with nationalized approach that the Patient-Centered Outcomes Research Institute will bring, Clyde Yancy, member of the new institute’s Methodology Committee, suggests.
You may also be interested in...
Research involving drugs has been limited since the Patient-Centered Outcomes Research Institute began project funding, but institute Executive Director Joe Selby expects that to change as PCORI prepares to issue funding announcements for pragmatic trials.
While health technology assessment’s role primarily is to aid clinical and policy decision-making, it also has the potential to help prioritize the comparative effectiveness research agenda as well as inform trial designs, according to a recent article in the Journal of Clinical Oncology.
What started out as an exercise to show how comparative effectiveness research could be quickly adopted and help improve health outcomes ended up revealing that there remains a long way to go.